KRAS and mesothelioma: To date, divarasib (GDC-6036), sotorasib and the most recently reported Pan-KRAS inhibitor have been explored for the treatment of multiple solid tumors80–82, suggesting the feasibility of employing KRAS inhibitors in mesothelioma treatment.